Immunomodulatory effects of macrolide antibiotics in respiratory disease: Therapeutic implications for asthma and cystic fibrosis

Pediatric Drugs

Volumn 9, Issue 2, 2007, Pages 107-118

  Sharma, Sanjiv ^a   Jaffe, Adam ^b,c   Dixon, Garth ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEASE; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIN 1; EPIRUBICIN; ERYTHROMYCIN; MACROLIDE; METHYLPREDNISOLONE; NITRIC OXIDE; PLACEBO; RAPAMYCIN; ROXITHROMYCIN; TELITHROMYCIN; TROLEANDOMYCIN;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHIOLITIS; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DRUG ANTAGONISM; DRUG BINDING; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG ISOLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOMODULATION; INFLAMMATION; LOW DRUG DOSE; LUNG FUNCTION TEST; MORBIDITY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNSPECIFIED SIDE EFFECT; WHEEZING;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ASTHMA; BRONCHOCONSTRICTION; CHEMOKINES; CHILD; CLINICAL TRIALS; CYSTIC FIBROSIS; HUMANS; INFLAMMATION; MACROLIDES; NEUTROPHILS; NITRIC OXIDE; RESPIRATORY FUNCTION TESTS; SIGNAL TRANSDUCTION;

EID: 34247222091     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709020-00004     Document Type: Review

References (109)

1. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993 Jan; 122 (1): 1-9
2. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995 Apr; 151 (4): 1075-82
3. DiMango E, Ratner AJ, Bryan R, et al. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998 Jun 1; 101 (11): 2598-605
4. Weber AJ, Soong G, Bryan R, et al. Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function. Am J Physiol Lung Cell Mol Physiol 2001 Jul; 281 (1): L71-8
5. Corvol H, Fitting C, Chadelat K, et al. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2003 Jun; 284 (6): L997-1003
6. Dai Y, Dean TP, Church MK, et al. Desensitisation of neutrophil responses by systemic interleukin 8 in cystic fibrosis. Thorax 1994 Sep; 49 (9): 867-71
7. Saba S, Soong G, Greenberg S, et al. Bacterial stimulation of epithelial G-CSF and GM-CSF expression promotes PMN survival in CF airways. Am J Respir Cell Mol Biol 2002 Nov; 27 (5): 561-7
8. Stockley RA. Role of inflammation in respiratory tract infections. Am J Med 1995 Dec 29; 99 (6B): 8S-13S
9. Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990 Jul; 86 (1): 300-8
10. Meng QH, Springall DR, Bishop AE, et al. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 1998 Mar; 184 (3): 323-31
11. Gaston B, Ratjen F, Vaughan JW, et al. Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapy. Am J Respir Crit Care Med 2002 Feb 1; 165 (3): 387-90
12. Payne DN. Nitric oxide in allergic airway inflammation. Curr Opin Allergy Clin Immunol 2003 Apr; 3 (2): 133-7
13. Bush A, Tiddens H, Silverman M. Clinical implications of inflammation in young children. Am J Respir Crit Care Med 2000 Aug; 162 (2 Pt 2): S11-4
14. Payne DN, Wilson NM, James A, et al. Evidence for different subgroups of difficult asthma in children. Thorax 2001 May; 56 (5): 345-50
15. Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force [published erratum appears in Allergy 2001 Dec; 56 (12): 1229]. Allergy 2001 Sep; 56 (9): 813-24
16. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993; 307 (6910): 982-6
17. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310 (6989): 1225-9
18. Vuillermin P, South M, Robertson C. Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children. Cochrane Database Syst Rev 2006 Jul 19; 3: CD005311
19. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006 Feb 16; 354 (7): 697-708
20. Turner H, Kinet JP. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature 1999 Nov 25; 402 (6760 Suppl.): B24-30
21. Ammit AJ, Bekir SS, Johnson PR, et al. Mast cell numbers are increased in the smooth muscle of human sensitized isolated bronchi. Am J Respir Crit Care Med 1997 Mar; 155 (3): 1123-9
22. Cazzola M, Polosa R. Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol 2006 Feb; 6 (1): 43-50
23. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990 Oct 11; 323 (15): 1033-9
24. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999 Oct 1; 99 (1): 23-33
25. Chanez P, Bousquet J, Couret I, et al. Increased numbers of hypodense alveolar macrophages in patients with bronchial asthma. Am Rev Respir Dis 1991 Oct; 144 (4): 923-30
26. Fuller RW. The role of the alveolar macrophage in asthma. Respir Med 1989 May; 83 (3): 177-8
27. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J Exp Med 1989 Aug 1; 170 (2): 499-509
28. Bentley AM, Hamid Q, Robinson DS, et al. Prednisolone treatment in asthma: reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996 Feb; 153 (2): 551-6
29. Nickel R, Beck LA, Stellato C, et al. Chemokines and allergic disease. J Allergy Clin Immunol 1999 Oct; 104 (4 Pt 1): 723-42
30. Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994 Apr; 149 (4 Pt 1): 953-9
31. Elwood W, Lotvall JO, Barnes PJ, et al. Effect of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats. Am Rev Respir Dis 1992 Jun; 145 (6): 1289-94
32. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev 1999 Jun; 51 (2): 213-340
33. Birrell MA, Battram CH, Woodman P, et al. Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways. Respir Res 2003; 4 (1): 3
34. Stamler DA, Edelstein MA, Edelstein PH. Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob Agents Chemother 1994 Feb; 38 (2): 217-22
35. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000; 50 (4): 285-95
36. Hatipoglu U, Rubinstein I. Low-dose, long-term macrolide therapy in asthma: an overview. Clin Mol Allergy 2004; 2 (1): 4
37. Niven AS, Argyros G. Alternate treatments in asthma. Chest 2003; 123 (4): 1254-65
38. Nalca Y, Jansch L, Bredenbruch F, et al. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PA01: a global approach. Antimicrob Agents Chemother 2006 May; 50 (5): 1680-8
39. Schultz MJ, Speelman P, Zaat S, et al. Erythromycin inhibits tumor necrosis factor alpha and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob Agents Chemother 1998 Jul; 42 (7): 1605-9
40. Brugiere O, Milleron B, Antoine M, et al. Diffuse panbronchiolitis in an Asian immigrant. Thorax 1996 Oct; 51 (10): 1065-7
41. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994 Jun; 49 (6): 531-2
42. Kobayashi H, Takeda H, Sakayori S, et al. Study on azithromycin in treatment of diffuse panbronchiolitis. Kansenshogaku Zasshi 1995 Jun; 69 (6): 711-22
43. Takeda H, Miura H, Kawahira M, et al. Long-term administration study on TE-031 (A-56268) in the treatment of diffuse panbronchiolitis. Kansenshogaku Zasshi 1989 Jan; 63 (1): 71-8
44. Jaffe A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998 Feb 7; 351 (9100): 420
45. Ordonez CL, Stulbarg M, Grundland H, et al. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001 Jul; 32 (1): 29-37
46. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002 Mar; 57 (3): 212-6
47. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002 Sep 28; 360 (9338): 978-84
48. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003 Oct 1; 290 (13): 1749-56
49. Pirzada OM, McGaw J, Taylor CJ, et al. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J Cyst Fibros 2003 Jun; 2 (2): 69-71
50. Clement A, Tamalet A, Le Roux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax 2006; 61 (10): 895-902
51. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001 Jun; 31 (6): 464-73
52. Saiman L, Mayer-Hamblett N, Campbell P, et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005 Oct 15; 172 (8): 1008-12
53. Cystic Fibrosis Foundation home page [online]. Available from URL: http://www.cff.org [Accessed 2007 Feb 28]
54. Dinwiddie R. Anti-inflammatory therapy in cystic fibrosis. J Cyst Fibros 2005; 4 Suppl. 2: 45-8
55. Kaplan MA, Goldin M. The use of triacetyloleandomycin in chronic infectious asthma. In: Welch H, Marti-Ibanez F, editors. Antibiotic annual 1958-59. New York: Interscience Publishers, Inc., 1959: 273-6
56. Itkin IH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970 Mar; 45 (3): 146-62
57. Zeiger RS, Schatz M, Sperling W, et al. Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma. J Allergy Clin Immunol 1980 Dec; 66 (6): 438-46
58. Nelson HS, Hamilos DL, Corsello PR, et al. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 1993 Feb; 147 (2): 398-404
59. Eitches RW, Rachelefsky GS, Katz RM, et al. Methylprednisolone and troleandomycin in treatment of steroid-dependent asthmatic children. Am J Dis Child 1985 Mar; 139 (3): 264-8
60. Ball BD, Hill MR, Brenner M, et al. Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Ann Allergy 1990 Jul; 65 (1): 37-45
61. Shimizu T, Kato M, Mochizuki H, et al. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 1994 Aug; 106 (2): 458-61
62. Fost DA, Leung DY, Martin RJ, et al. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol 1999 Jun; 103 (6): 1031-5
63. Rosenberg SM, Gerhard H, Grunstein MM, et al. Use of TAO without methylprednisolone in the treatment of severe asthma. Chest 1991 Sep; 100 (3): 849-50
64. Miyatake H, Taki F, Taniguchi H, et al. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 1991 Mar; 99 (3): 670-3
65. Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000 Jun; 84 (6): 594-8
66. Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647): the first ketolide. J Antimicrob Chemother 2003 Mar; 51 (3): 497-511
67. Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006 Apr 13; 354 (15): 1589-600
68. Emre U, Roblin PM, Gelling M, et al. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med 1994 Jul; 148 (7): 727-32
69. Hahn DL, Bukstein D, Luskin A, et al. Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma. Ann Allergy Asthma Immunol 1998 Jan; 80 (1): 45-9
70. Kaneko K, Yamashiro Y, Maruyama T, et al. Chlamydia pneumoniae infection in children with persistent cough. Arch Dis Child 1999 Jun; 80 (6): 581-2
71. Sakito O, Kadota J, Kohno S, et al. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63 (1): 42-8
72. Khair OA, Devalia JL, Abdelaziz MM, et al. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995 Sep; 8 (9): 1451-7
73. Tsai WC, Rodriguez ML, Young KS, et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 2004 Dec 15; 170 (12): 1331-9
74. Li Y, Azuma A, Takahashi S, et al. Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice. Chest 2002 Dec; 122 (6): 2137-45
75. Lin HC, Wang CH, Liu CY, et al. Erythromycin inhibits beta2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils. Respir Med 2000 Jul; 94 (7): 654-60
76. Okubo Y. Macrolides reduce the expression of surface Mac-1 molecule on neutrophil. Kurume Med J 1997; 44 (2): 115-23
77. Kawasaki S, Takizawa H, Ohtoshi T, et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998 Jun; 42 (6): 1499-502
78. Brennan S, Cooper D, Sly PD. Directed neutrophil migration to IL-8 is increased in cystic fibrosis: a study of the effect of erythromycin. Thorax 2001 Jan; 56 (1): 62-4
79. Uriarte SM, Molestina RE, Miller RD, et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha. J Infect Dis 2002 Jun 1; 185 (11): 1631-6
80. Labro MT, el Benna J, Babin-Chevaye C. Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 1989 Oct; 24 (4): 561-72
81. Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis 1989 May; 159 (5): 966-73
82. Culic O, Erakovic V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002 Aug 30; 450 (3): 277-89
83. Aoshiba K, Nagai A, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 1995 Apr; 39 (4): 872-7
84. Mitsuyama T, Hidaka K, Furuno T, et al. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. Int Arch Allergy Immunol 1997 Oct; 114 (2): 111-5
85. Tamaoki J, Kondo M, Kohri K, et al. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol 1999 Sep 1; 163 (5): 2909-15
86. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. Eur Respir J 1998 Jul; 12 (1): 57-63
87. Yatsunami J, Fukuno Y, Nagata M, et al. Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells. Clin Exp Metastasis 1999 Jun; 17 (4): 361-7
88. Yatsunami J, Tsuruta N, Hara N, et al. Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett 1998 Sep 25; 131 (2): 137-43
89. Fujitani Y, Trifilieff A. In vivo and in vitro effects of SAR 943, a rapamycin analogue, on airway inflammation and remodeling. Am J Respir Crit Care Med 2003 Jan 15; 167 (2): 193-8
90. Feldman C, Anderson R, Theron A, et al. The effects of ketolides on bioactive phospholipid-induced injury to human respiratory epithelium in vitro. Eur Respir J 1999 May; 13 (5): 1022-8
91. Lallemand JY, Stoven V, Annereau JP, et al. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet 1997 Sep 6; 350 (9079): 711-2
92. Gant TW, O'Connor CK, Corbitt R, et al. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 1995 Aug; 133 (2): 269-76
93. Tamaoki J, Isono K, Sakai N, et al. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 1992 Feb; 5 (2): 234-8
94. Tagaya E, Tamaoki J, Kondo M, et al. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002 Jul; 122 (1): 213-8
95. Advenier C, Sarria B, Naline E, et al. Contractile activity of three endothelins (ET-1, ET-2 and ET-3) on the human isolated bronchus. Br J Pharmacol 1990 May; 100 (1): 168-72
96. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997 Jul; 156 (1): 266-71
97. Barker PM, Gillie DJ, Schechter MS, et al. Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium. Am J Respir Crit Care Med 2005 Apr 15; 171 (8): 868-71
98. Equi AC, Davies JC, Painter H, et al. Exploring the mechanisms of macrolides in cystic fibrosis. Respir Med 2006 Apr; 100 (4): 687-97
99. Engelhardt JF, Yankaskas JR, Ernst SA, et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet 1992 Nov; 2 (3): 240-8
100. Basbaum CB, Jany B, Finkbeiner WE. The serous cell. Annu Rev Physiol 1990; 52: 97-113
101. Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997 Feb 21; 88 (4): 553-60
102. Ashitani J, Mukae H, Nakazato M, et al. Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis. Eur Respir J 1998 Jan; 11 (1): 104-11
103. Hiratsuka T, Mukae H, Iiboshi H, et al. Increased concentrations of human beta-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 2003 May; 58 (5): 425-30
104. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995 Jan; 19 (1): 10-5
105. Davies J, Dewar A, Bush A, et al. Reduction in the adherence of Pseudomonas aeruginosa to native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition. Eur Respir J 1999 Mar; 13 (3): 565-70
106. Schroeder TH, Lee MM, Yacono PW, et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci U S A 2002 May 14; 99 (10): 6907-12
107. Davies JC, Stern M, Dewar A, et al. CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. Am J Respir Cell Mol Biol 1997 Jun; 16 (6): 657-63
108. Nakashio S, Susa C, Qiu S, et al. Antimicrobial activity of clarithromycin and its effect on bacterial adherence to medical material. Jpn J Antibiot 1993 Jun; 46 (6): 428-36
109. Baumann U, Fischer JJ, Gudowius P, et al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection 2001 Jan-Feb; 29 (1): 7-11